65,437 trials
Idiopathic Pulmonary Fibrosis
Primary: Acceptability of patientMpower Platform From Patient & Healthcare Professional Perspective — 3; 1; 1; 4 Participants
Influenza, Human
Primary: The Geometric Mean Titer (GMT) Ratio of Each Virus Strain. — 370.0; 311.7; 436.8; 589.1 Geometric Mean Titer
Hematologic Malignancies
Primary: Safety Measures — 0 participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites — 133; 109; 83.9; 156 nanograms per milliliter (ng/mL)
Hypercholesterolemia · Dyslipidemia
Primary: Number of Participants With Dose Limiting and Intolerable Treatment-Related Adverse Events (AEs) — 0; 0; 0; 0 participants
Colorectal Cancer
Primary: Progression-Free Survival — 9.14 Months
Multiple Sclerosis
Primary: Number of Subjects With Active (New or Enlarging) T2 Lesions Assessed by Magnetic Resonance Imaging (MRI) at Month 12 — 4; 7 Participants — p=0.271
Vaginitis
Primary: Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit — 275; 268; 27; 41…
Dermatitis, Atopic
Primary: Time to Onset of Asthma During the Treatment Period — NA; NA months — p==0.991
Malformations
Primary: Number of Infants With Major Congenital Malformations — 12; 3382; 33950 infants
Breast Cancer
Primary: Local Recurrence Rate — 0 Participants
Chronic Lymphocytic Leukemia
Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 6; 1 number of patients without DLT
Healthy Participants
Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 266.83; 198.22; 481.11; 668.87 nanograms per milliliter (ng/mL)
Paravertebral Peripheral Nerve Block · Acute Pain Management
Primary: Opioid Consumption at 24 Hours Postoperatively — 5.75; 6.38 mg — p=0.643